At the news
? BEARISHIMPACT 9/10 25-NSE filed Jul 15, 2026 at 09:56 ET
Nasdaq filed a Form 25-NSE to delist Catalyst Pharmaceuticals' common stock under Rule 12d2-2(a)(3), effective immediately on July 15, 2026. This is a mandatory removal initiated by the exchange, not a voluntary delisting, and represents a severe negative event for a $3.9B market-cap company.
- Nasdaq Stock Market LLC filed Form 25-NSE to remove Catalyst Pharmaceuticals' common stock from listing and registration.
- The delisting is under 17 CFR 240.12d2-2(a)(3), which covers securities that have been redeemed, retired, or matured, but here it is an exchange-initiated removal.
- The filing was made effective on July 15, 2026.
- Catalyst Pharmaceuticals has a market cap of approximately $3.9B, making this a significant event.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access